Scientific Articles

ABSTRACTBackgroundIn the pivotal Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality rates, leading to…

Awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) has increased over the years due to diagnostic and therapeutic developments. Timely initiation of novel…

Simple SummaryLight-chain (AL) amyloidosis is a rare disease similar to the more common disease, multiple myeloma (MM). Both are caused by proliferation of…

A 76-year-old woman was found to have abnormally enlarged and calcified bilateral axillary lymph nodes on a screening mammogram (Figure 1). These correlated with…

Extract A 76-year-old woman was found to have abnormally enlarged and calcified bilateral axillary lymph nodes on a screening mammogram (Figure 1). These…

Cardiac amyloidosis used to be considered an ultra-rare disease with no treatment options. No longer. Advances in noninvasive testing have led to greater awareness…

IntroductionTransthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM…

AL amyloidosis is caused by the excessive production of nonfunctional immunoglobulins, leading to the formation of amyloid fibrils that damage vital organs,…

About the episodeIn this video, Prof Philip Hawkins (University College London, London, UK), addresses some important key questions surrounding amyloidosis, a…

AimsHELIOS-A was a Phase 3, open-label study of vutrisiran, an RNA interference therapeutic, in patients with hereditary transthyretin (ATTRv) amyloidosis with…